Persistent genomic instability in peripheral blood lymphocytes from hodgkin lymphoma survivors

Environmental and Molecular Mutagenesis

Volumn 53, Issue 4, 2012, Pages 271-280

  Salas, C ^a,b   Niembro, A ^a   Lozano, V ^c   Gallardo, E ^d   Molina, B ^a   Sanchez S ^a   Ramos, S ^a   Carnevale, A ^e   Perez Vera P ^a   Rivera Luna, R ^a   Frias, S ^a,f  

^a INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^d HOSPITAL GENERAL DE MÉXICO   (Mexico)

^e INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^f INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

Author keywords

Aneuploidy; Chemotherapy; G bands; Genotoxicity; Structural chromosomal aberrations

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINCRISTINE SULFATE;

ADOLESCENT; ANEUPLOIDY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVOR; CELL EXPANSION; CHILD; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DNA DAMAGE; GENOMIC INSTABILITY; HODGKIN DISEASE; HUMAN; MALE; METAPHASE; MULTIPLE CYCLE TREATMENT; PERIPHERAL LYMPHOCYTE; PREMEDICATION; PRESCHOOL CHILD; SCHOOL CHILD;

ADULT; ANEUPLOIDY; CASE-CONTROL STUDIES; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; HODGKIN DISEASE; HUMANS; LYMPHOCYTES; MALE; MECHLORETHAMINE; PREDNISONE; PROCARBAZINE; STATISTICS, NONPARAMETRIC; VINCRISTINE;

EID: 84859614012     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.21691     Document Type: Article

References (57)

1. Aguilera A, Gómez-González B. 2008. Genome instability: A mechanistic view of its causes and consequences. Nat Rev Genet 9: 204-217.
2. Allan JM, Travis LB. 2005. Mechanisms of therapy-related carcinogenesis. Nat Rev 5: 943-955.
3. Arden-Close E, Pacey A, Eiser C. 2010. Health-related quality of life in survivors of lymphoma: A systematic review and methodological critique. Leuk Lymphoma 51: 628-640.
4. Balis MF, Holcenberg JS, Poplack DG. 1993. General principles of chemotherapy. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia: JB Lippincott. pp 203-245.
5. Barrios L, Caballín MR, Miró R, Fuster C, Berrozpe G, Subías A, Batlle X, Egozcue J. 1988. Chromosome abnormalities in peripheral blood lymphocytes from untreated Hodgkin's patients. Hum Genet 78: 320-324.
6. Bilban-Jakopin C, Bilban M. 2001. Genotoxic effects of radiotherapy and chemotherapy on circulating lymphocytes in patients with Hodgkin's disease. Mutat Res 497: 81-88.
7. Blanco JG, Dervieux T, Edick MJ, Mehta PK, Rubnitz JE, Shurtleff S, Raimondi SC, Behm FG, Pui CH, Relling MV. 2001. Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci USA 98: 10338-10343.
8. Boffetta P, Van der Hel O, Norppa H, Fabianova E, Fucic A, Gundy S, Lazutka J, Cebulska-Wasilewska A, Puskailerova D, Znaor A, Kelecsenyi Z, Kurtinaitis J, Rachtan J, Forni A, Vermeulen R, Bonassi S. 2007. Chromosomal aberrations and cancer risk: Results of a cohort study from Central Europe. Am J Epidemiol 165: 36-43.
9. Bonassi S, Znaor A, Norppa H, Hagmar L. 2004. Chromosomal aberrations and risk of cancer in humans: An epidemiologic perspective. Cytogenet Genome Res 104: 376-382.
10. Cimino MC, Tice RR, Liang JC. 1986. Aneuploidy in mammalian cells in vivo. Mutat Res 167: 107-122.
11. Constine LS, Tarbell N, Hudson MM, Schartwz C, Fisher SG, Muhs AG, Basu SK, Kun LE, Ng A, Mauch P, Sandhu A, Culakova E, Lyman G, Mendenhall N. 2008. Subsequent malignancies in children treated for Hodgkin's disease: Associations with gender and radiation dose. Int J Radiat Oncol Biol Phys 72: 24-33.
12. Dennis TR, Stock AD, Winberg CD, Sheibani K, Rappaport H. 1989. Cytogenetics studies of Hodgkin's disease: Analysis of involved lymph nodes from 12 patients. Cancer Genet Cytogenet 37: 201-208.
13. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. 2003. Hodgkin's lymphoma: Biology and treatment strategies for primary, refractory and relapsed disease. Hematology 2: 225-247.
14. Eastmond DA, Pinkel D. 1990. Detection of aneuploidy-inducing agents in human lymphocytes using fluorescence in situ hybridization with chromosome-specific DNA probes. Mutat Res 234: 303-318.
15. Fairley TL, Hawk H, Pierre S. 2010. Health behaviors and quality of life of cancer survivors in Massachusetts, 2006: Data use for comprehensive cancer control. Prev Chronic Dis 7: A09.
16. Foss Abrahamsen AF, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, Kvaloy S. 2002. Long-term risk of second malignancy after treatment of Hodgkin's disease: The influence of treatment, age and follow-up time. Ann Oncol 13: 1786-1791.
17. Frías S. 2002. Consecuencias genéticas del tratamiento antineoplásico en células germinales de pacientes con cáncer. In: Rivera Luna R, editor. Oncología pediátrica: Conceptos básicos y clínicos. México: Intersistemas SA de C.V. pp 279-302.
18. Frias S, Van Hummelen P, Meistrich ML, Lowe XR, Hagemeister FB, Shelby MD, Bishop JB, Wyrobek AJ. 2003. NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18 and 21. Cancer Res 63: 44-51.
19. Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, Donaldson S, Meadows AT, Robison LL, Neglia JP. 2010. Subsequent neoplasms in 5-year survivors of childhood cancer: The childhood cancer survivor study. J Natl Cancer Inst 102: 1083-1095.
20. Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M. 2006. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-years results, late toxicity, and second tumors. Clin Cancer Res 12: 529-535.
21. Hagmar L, Strömberg U, Bonassi S, Hansteen IL, Knudsen LE, Lindholm C, Norppa H. 2004. Impact of types of lymphocyte chromosomal aberrations on human cancer risk: Results from Nordic and Italian cohorts. Cancer Res 64: 2258-2263.
22. Hecht F, McCaw BK, Peakman D, Robinson A. 1979. New translocations in human lymphocytes: A mutagen monitoring system. Environ Health Perspect 31: 19-22.
23. Heng HH, Liu G, Bremer S, Ye KJ, Stevens J, Ye CJ. 2006. Clonal and nonclonal chromosome aberrations and genome variation and aberration. Genome 49: 195-204.
24. Huang L, Snyder AR, Morgan WF. 2003. Radiation-induced genomic instability and its implications for radiation carcinogenesis. Oncogene 22: 5848-5854.
25. Hudson MM, Donaldson SS. 1997. Hodgkin's disease. Pediatr Clin North Am 44: 891-906.
26. Hudson MM, Donaldson SS. 1999. Treatment of pediatric Hodgkin's lymphoma. Semin Hematol 36: 313-323.
27. Jenkin D, Greenberg M, Fitzgerald A. 1996. Second malignant tumours in childhood Hodgkin's disease. Med Pediatr Oncol 26: 373-379.
28. Juberg R, Knops J, Mowrey P. 1985. Increased frequency of lymphocytic mitotic nondisjunction in recurrent spontaneous aborters. J Med Genet 22: 32-35.
29. Leone G, Fianchi L, Pagano L, Voso MT. 2010. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact 184: 39-45.
30. Leopardi P, Marcon F, Dobrowolny G, Zijno A, Crebelli R. 2002. Influence of donor age on vinblastine-induced chromosome malsegregation in cultured peripheral lymphocytes. Mutagenesis 17: 83-88.
31. Linch DC, Gosden RG, Tulandi T, Tan SL, Hancock SL. 2000. Hodgkin's lymphoma: Choice of therapy and late complications. Hematology 3: 205-221.
32. Little JB. 2003. Genomic instability and bystander effects: A historical perspective. Oncogene 23: 173-181.
33. Lorimore SA, Coates PJ, Wright EG. 2003. Radiation-induced genomic instability and bystander effects: Inter-related nontargeted effects of exposure to ionizing radiation. Oncogene 22: 7058-7069.
34. Magrath IT, Johnson JF. 1993. Lymphoma in children. In: Cuitkovic E, Droz JP, Armand JP, Khovry S, editors. Handbook of Chemotherapy in Clinical Oncology. Paris: Rhone-Poulenc Rorer, Scientific Communication International. pp 702-715.
35. Meistrich ML. 1993. Effects of chemotherapy and radiotherapy on spermatogenesis. Eur Urol 23: 136-142.
36. Mitelman F. 1991. Catalog of chromosome aberrations in cancer. USA: Wiley-Liss. pp 485, 489, 503, 1082, 1259, 1286.
37. M'Kacher R, Girinsky T, Koscielny S, Dossou J, Violot D, Béron-Gaillard N, Ribrag V, Bourhis J, Bernheim A, Parmentier C, Carde P. 2003. Baseline and treatment-induced chromosomal abnormalities in peripheral blood lymphocytes of Hodgkin's lymphoma patients. Int J Radiat Oncol Biol Phys 57: 321-326.
38. M'Kacher R, Andreoletti L, Flamant S, Milliat F, Girinsky T, Dossou D, Violot D, Assaf E, Clausse B, Koscielny S, Bourhis J, Bosq J, Bernheim A, Parmentier C, Carde P. 2010. JC human polyomavirus is associated to chromosomal instability in peripheral blood lymphocytes of Hodgkin's lymphoma patients and poor clinical outcome. Ann Oncol 21: 826-832.
39. Muwakkit S, Geara F, Nabbout B, Farah RA, Shabb NS, Hajjar T, Khogali M. 1999. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy. Radiother Oncol Invest 7: 365-373.
40. Nagai M, Abe T, Seki S, Minato K, Watanabe S, Shimoyama M. 1986. Karyotype aberrations and surface markers analyses of the tumor cells of Hodgkin's disease: A case report and review of literature. Jpn J Clin Oncol 16: 397-406.
41. Norppa H, Bonassi S, Hansteen IL, Hagmar L, Strömberg U, Rösner P, Boffetta P, Lindholm C, Gundy S, Lazutka J, Cebulska-Wasilewska A, Fabiánová E, Srám RJ, Knudsen LE, Barale R, Fucic A. 2006. Chromosomal aberrations and SCEs as biomarkers of cancer risk. Mutat Res 600: 37-45.
42. Papa G, Mauro FR, Anselmo AP, Cimino G, Alimena G, Amadori S, D'Arcangelo E, Giannarelli E, Bosi A, Bellesi G. 1984. Acute leukemia in patients treated for Hodgkin's disease. Br J Hematol 58: 43-52.
43. Preston RJ. 2005. Bystander effects, genomic instability, adaptive response, and cancer risk assessment for radiation and chemical exposures. Toxicol Appl Pharmacol 207 (Suppl 2): 550-556.
44. Rivera Luna R. 2006. Conceptos epidemiológicos del cáncer infantil en México. In: Rivera Luna R, editors. Hemato-Oncología Pediátrica. México: Editores de textos Mexicanos. pp 5-18.
45. Robbins WA, Meistrich ML, Moore D, Hagemeister FB, Weier HU, Cassel MJ, Wilson G, Eskenazi B, Wyrobek AJ. 1997. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Nat Genet 16: 74-77.
46. Ryabchenko N, Nasanova V, Antoschina M, Fesenko E, Kondrashova T, Ivanova T, Pavlov V, Ryabikhina N, Terekhova A. 2003. Persistence of chromosome aberrations in peripheral lymphocytes from Hodgkin's lymphoma remission patients. Int J Radiat Biol 79: 251-257.
47. Santoro A, Viviani S. 1993. Hodgkin's disease. In: Cuitkovic E, Droz JP, Armand JP, Khovry S, editors. Handbook of Chemotherapy in Clinical Oncology. Paris: Rhone-Poulenc Rorer, Scientific Communication International. pp 695-701.
48. Shaffer L, Slovak M, Campbell L. 2009. ISCN (2009). In: Karger, editor. An International System for Human Nomenclature. Switzerland: ISCN. pp 86-87.
49. Shen Z. 2011. Genomic instability and cancer: An introduction. J Cell Mol Biol 3: 1-3.
50. Sieniawski M, Franklin J, Nogova L, Glossmann JP, Schober T, Nisters-Backes H, Diehl V, Josting Al. 2007. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 25: 2000-2005.
51. Smith LM, Evans JW, Mori M, Brown JM. 1992. The frequency of translocations after treatment for Hodgkin's disease. Int J Radiat Oncol Biol Phys 24: 737-742.
52. Thomson AB, Wallace WHB. 2002. Treatment of pediatric Hodgkin's disease: A balance of risks. Eur J Cancer 38: 468-477.
53. Van der Velden VHJ, Hochhaus A, Cazzaninga G, Szczepanski T, Gabert J, Van Dongen JJ. 2003. Detection of minimal residual disease in hematologic malignancies by real time quantitative PCR: Principles, approaches, and laboratory aspects. Leukemia 17: 1013-1034.
54. Witt KL, Bishop JB. 1996. Mutagenicity of anticancer drugs in mammalian germ cells. Mutat Res 355: 209-234.
55. Worrilow LJ, Smith AG, Scott K, Andersson M, Ashcroft AJ, Dores GM, Glimelius B, Holowaty E, Jackson GH, Jones GL, Lynch CF, Morgan G, Pukkala E, Scott D, Storm HH, Taylor PR, Vyberg M, Willet E, Travis LB, Allan JM. 2008. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet 45: 142-146.
56. Wright EG. 1999. Inherited and inducible chromosomal instability: A fragile bridge between genome integrity mechanisms and tumorigenesis. J Pathol 187: 19-27.
57. Yuen KW, Desai A. 2008. The wages of CIN. J Cell Biol 180: 661-663.